• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 10th June 2019

Moving the Needle on Value – OHE Launches Research on US Value-Based Healthcare

At the recent ISPOR Annual Conference, OHE’s Chief Executive, Professor Graham Cookson announced a new programme of work on Value 2.0: Assessing the Value of US Healthcare to be funded by PhRMA. Graham was joined by the Innovation and Value…

Tim 3
Tim Watson
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

At the recent ISPOR Annual Conference, OHE’s Chief Executive, Professor Graham Cookson announced a new programme of work on Value 2.0: Assessing the Value of US Healthcare to be funded by PhRMA. Graham was joined by the Innovation and Value Institute’s Executive Director Jenn Bright, and Harvard Medical School Professor Bapu Jena.

OHE and The Value Collaborative, an initiative of America’s biopharmaceutical companies, co-hosted a cocktail reception at the recent ISPOR conference in New Orleans entitled Moving the Needle on Value.

OHE’s Chief Executive, Professor Graham Cookson, used the event to announce a new programme of work assessing the value of US healthcare. Graham was joined by the Innovation and Value Initiative’s Executive Director Jenn Bright, and Harvard Medical School Professor Bapu Jena.

The US spends 18% of GDP on healthcare, totalling $3.5 trillion. Healthcare costs in the US increased by 4% per annum in 2017 and are predicted to continue escalating. There is wide agreement that the growth in healthcare costs is unsustainable.

Graham asked “how can we move the needle on value?” Value-based healthcare, in which healthcare is organised, delivered, and reimbursed to maximise value for patients, has long been talked about. To date, value assessment, the practice of measuring the relative costs and benefits of interventions, has been applied almost exclusively to medicines and medical technology.

Similarly, there has been significant political and media attention given to the cost of medicines. But, this attention in terms of policy and evidence generation to medicines is disproportionate to the impact on spending. Medicines represent about 14% of US healthcare expenditure, roughly the same as they did in 1960, whilst spending on hospital care represents the largest share of current healthcare spending at $1.1 trillion. Additionally, there are numerous studies that provide examples of spending on care that provides no or low value (e.g. inappropriate diagnostic testing), estimated to cost hundreds of billions of dollars each year.

Value-based healthcare is a sound principle but for it to work it requires: (i) that the full value of healthcare is recognised and adequately measured, and (ii) a fair mechanism for evaluating all spending across the spectrum of healthcare equally. A new coherent framework for a widescale approach to achieving value is needed to truly move the needle.

A key challenge to this approach is the lack of alignment on what is meant by value and for whom. That’s the big takeaway from the University of Utah’s recent The State of Value in U.S. Health Care survey. They asked more than 5,000 patients, more than 600 physicians, and more than 500 employers who provide medical benefits across the US how they think about the quality, service, and cost of healthcare. The study made it clear that there is no consensus on what is meant by value and quality of care. The Innovation and Value Initiative’s Jenn Bright raised the issue that patients feel excluded from the decision-making process, and they feel that the current system fails to recognise what is of value to patients and their families and carers.

Harvard’s Bapu Jena argued that research has shown that there is often no correlation between healthcare expenditure and the quality of care. Moreover, many of the advances in outcomes such as life expectancy have been driven by technological and pharmaceutical innovation, and less so by changes in medical practice. Bapu then offered some personal reflections on why there is much greater attention given to the value, and value for money, of pharmaceutical expenditure than on other aspects of healthcare. 

The event was well attended by a mix of academics, policy specialists, and industry professionals, who were invited to share their thoughts on the topic. OHE’s Adrian Towse summarised the short talks and closed the event by inviting attendees to collaborate with OHE on our forthcoming research. The invitation is open to anybody who is interested in understanding more about elements of value and in value-based healthcare.

There were three takeaway messages from the event. First, that in the absence of perfect markets, value assessment is necessary to ensure that healthcare expenditure is spent optimally. Second, that in order to do that, we need to ensure that we have a common understanding of value, capturing what matters most to patients and society. And third, that this will only deliver major gains if it’s applied across all aspects of healthcare expenditure.

The drinks and canapes at the event were sponsored by The Value Collaborative – an initiative of America’s biopharmaceutical companies.

  • OHE Consulting
  • Policy, Organisation and…
  • Events

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!